New perspectives for targeting RAF kinase in human cancer

Nature Reviews Cancer 17, 676 (2017). doi:10.1038/nrc.2017.79 Authors: Zoi Karoulia, Evripidis Gavathiotis & Poulikos I. Poulikakos The discovery that a subset of human tumours is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics. The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research